Editor’s note: Pending an FDA decision, 23andMe no longer offers new customers access to health reports referred to in this post. Customers who purchased prior to November 22, 2013 will still be able to see their health reports, but those who purchased after that time will not. Those customers will have access to ancestry information as well as access to their uninterpreted raw data.
Progressive supranuclear palsy (PSP) is a rare movement disorder caused by damage to certain areas of the brain. People with PSP experience increasing difficulty balancing and walking and suffer from frequent falls, in addition to varying vision, mood, and cognitive problems. PSP is similar to Parkinson’s disease but is much rarer — about 20,000 people in the United States are currently diagnosed with PSP.
As with Parkinson’s disease, the development of PSP is complex and influenced by many genetic and environmental factors. One genetic factor in particular, a variant in the MAPT gene, has been repeatedly linked to the disease. The MAPT gene codes for a protein called tau that is found in abnormally high amounts in the neurons of people with PSP. Scientists believe there are multiple factors interacting in this region of the genome that affect PSP development, but little is known about this interaction and how other genetic variation might contribute to PSP risk.
To discover common genetic variants potentially influencing risk for this disease, an international team of researchers led by Gunter Höglinger of Philipps-Universitat in Germany studied more than 2,000 individuals of European descent diagnosed with PSP, comparing their DNA to that of nearly 7,000 healthy European individuals. The results, published last month in the journal Nature Genetics, reported several SNPs associated with the disease.
(23andMe customers can check their data for each variant in their Progressive Supranuclear Palsy Preliminary Research report. Not all variants are available on all versions of 23andMe’s genotyping platform.)
One of the SNPs reported by Höglinger’s team is located in MAPT and is closely linked to the already well-established variant for PSP risk. In this study, each copy of the G version of in MAPT was associated with about 5.5 times lower odds of the disease. The researchers suggest that much of this effect is due to the SNP’s strong correlation with the previously known MAPT variant.
In addition to the strong association at MAPT, the researchers identified three other genetic variants with smaller effects on PSP risk located in the STX6 (), EIF2AK3 (), and MOBP () genes. These genes have intriguing connections to PSP and other neurodegenerative diseases but further research is needed to determine the exact roles they play in the development of these conditions.
SNPwatch gives you the latest news about research linking various traits and conditions to individual genetic variations. These studies are exciting because they offer a glimpse into how genetics may affect our bodies and health; but in most cases, more work is needed before this research can provide information of value to individuals. For that reason it is important to remember that like all information we provide, the studies we describe in SNPwatch are for research and educational purposes only. SNPwatch is not intended to be a substitute for professional medical advice; you should always seek the advice of your physician or other appropriate healthcare professional with any questions you may have regarding diagnosis, cure, treatment or prevention of any disease or other medical condition.